Thus, we developed a model showing how PDCD11 helps C‐MYC resist SKP2‐mediated ubiquitination to maintain its high protein levels and oncogenic activity in cancer cells with p53 mutation, which highlights PDCD11 as a potential therapeutic target aimed at destroying “undruggable” C‐MYC[4c] for cancer treatment. This evidence concerns the gene SKP2 and cancer.